$30 million Series B financing led by InClin, Inc., a global contract research organization, with continued support from existing investors

由全球合同研究组织InClin, Inc.领投的3000万美元B轮融资，现有投资者继续提供支持

ASPIRE-HF, a Phase 2a study of THRV-1268 in heart failure with reduced ejection fraction and QTc prolongation, opens for enrollment in early 2027

ASPIRE-HF是一项评估THRV-1268在射血分数降低且QTc间期延长的心力衰竭患者中的IIa期研究，将于2027年初启动受试者入组。

Wave II, a Phase 2/3 study of THRV-1268 in Long QT Syndrome, completes enrollment of its first efficacy cohort, with data expected in early 2027

Wave II（一项在长QT综合征患者中开展的THRV-1268的2/3期研究）已完成首个疗效队列的入组，预计将于2027年初公布数据。

Thryv to present new data on SGK1 inhibition in cardiometabolic heart failure in a late-breaking science session at AHA Scientific Sessions 2026

Thryv将在2026年美国心脏协会（AHA）科学会议的晚期突破科学分会场上展示关于SGK1抑制在 cardiometabolic 心力衰竭中的新数据

SAN FRANCISCO

旧金山

,

，

Nov. 3, 2026

2026年11月3日

/PRNewswire/ -- Thryv Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies through its pipeline of potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1), today announced a $30 million Series B financing led by InClin, Inc., a global contract research organization, with continued support from existing investors.

/美通社/ -- 临床阶段生物科技公司Thryv Therapeutics Inc.今日宣布完成3000万美元B轮融资，本轮融资由全球合同研究组织InClin, Inc.领投，现有投资者继续提供支持。该公司正通过其血清糖皮质激素诱导激酶1（SGK1）强效高选择性抑制剂产品管线，开发针对遗传性通道病、心脏代谢疾病和心肌病的精准疗法。

The financing follows completion of enrollment of the first efficacy cohort in the Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome and a favorable review of the available Wave II data by the study's Independent Data Monitoring Committee (IDMC). Proceeds will support advancement of THRV-1268 into ASPIRE-HF (.

此次融资是在完成THRV-1268治疗长QT综合征的Wave II期2/3阶段研究中首个疗效队列的入组，并且该研究的独立数据监查委员会（IDMC）对现有Wave II数据进行积极评估之后进行的。所得资金将用于支持推进THRV-1268进入ASPIRE-HF研究。

A

A

ddressing

寻址

S

S

GK1-driven

GK1驱动的

P

P

rolonged QT and

QT间期延长和

I

我

mpaired

受损的

RE

回复

modeling in

建模于

H

H

eart

耳朵

F

F

ailure), a Phase 2a study in adults with symptomatic HFrEF and QTc prolongation, opening for enrollment in early 2027.

衰竭），一项针对伴有症状性射血分数降低的心力衰竭（HFrEF）及QTc间期延长的成年患者的2a期研究，将于2027年初启动入组。

Series B Financing

B轮融资

The Series B financing was led by InClin, Inc., a global contract research organization with operations in San Mateo, California and Sydney, Australia. In recent months, Thryv has worked with InClin to establish clinical operations in Australia, enabling initial patient enrollment in the ASPIRE-HF study early next year.

B轮融资由InClin, Inc.领投，这是一家全球性合同研究组织，在美国加利福尼亚州圣马特奥和澳大利亚悉尼设有运营机构。近几个月来，Thryv与InClin合作在澳大利亚建立临床运营体系，从而使得ASPIRE-HF研究能够在明年初启动首批患者入组。

Proceeds will fund the Phase 2a ASPIRE-HF study through a pre-specified analysis of safety and efficacy, including changes in QTc and established biomarkers of heart failure risk. InClin joins as a strategic investor, bringing clinical operating capability alongside capital, together with existing investors Fonds de solidarité FTQ, Amplitude Ventures, Investissement Québec, Lumira Ventures, adMare BioInnovations, CTI Life Sciences Fund, and Alexandria Venture Investments..

所得款项将用于资助ASPIRE-HF研究的2a期阶段，直至完成预先指定的安全性和有效性分析，包括QTc间期变化以及已确立的心力衰竭风险生物标志物的评估。InClin作为战略投资者加入，在提供资本的同时带来临床运营能力，与现有投资者FTQ团结基金、Amplitude Ventures、魁北克投资公司、Lumira Ventures、adMare BioInnovations、CTI生命科学基金以及Alexandria风险投资公司共同支持该项目。

ASPIRE-HF

ASPIRE-HF

ASPIRE-HF is a Phase 2a, double-blind, randomized, placebo-controlled study evaluating the safety and pharmacokinetics of THRV-1268 and its effects on markers of arrhythmic risk, cardiac function, and cardiac remodeling in adults on GDMT with symptomatic HFrEF and QTc prolongation. Participants will be randomized to one of two dose levels of THRV-1268 or placebo over a 24-week treatment period, with a pre-specified early efficacy evaluation at Week 6..

ASPIRE-HF 是一项 IIa 期、双盲、随机、安慰剂对照研究，旨在评估 THRV-1268 在接受指南指导的药物治疗（GDMT）、伴有症状性射血分数降低的心力衰竭（HFrEF）及 QTc 间期延长的成年患者中的安全性、药代动力学，以及其对心律失常风险标志物、心脏功能和心脏重构的影响。参与者将在 24 周的治疗期内被随机分配至两个 THRV-1268 剂量组之一或安慰剂组，并在第 6 周进行预先指定的早期疗效评估。

Additional information will be available at

更多信息将在以下位置提供

www.aspire-hf.com

www.aspire-hf.com

.

。

'ASPIRE-HF is the culmination of years of work to establish SGK1 as a therapeutic target,' said Amy Sehnert, MD, FACC, Chief Medical Officer of Thryv Therapeutics. 'Human genetic and preclinical evidence, together with Phase 1 results demonstrating QT interval shortening in obese individuals, supports expanding our clinical program into heart failure.

“ASPIRE-HF 项目是多年来致力于确立 SGK1 为治疗靶点的成果结晶，”Thryv Therapeutics 首席医学官 Amy Sehnert 博士（美国心脏病学会会员）表示。“人类遗传学和临床前证据，以及显示肥胖个体 QT 间期缩短的 I 期临床试验结果，共同支持我们将临床研究计划拓展至心力衰竭领域。”

Patients living with HFrEF and a prolonged QTc carry a compounded burden: high residual morbidity on current standard of care, rapid and progressive cardiac failure, electrical instability, and a heightened risk of sudden cardiac death. This financing allows us to begin addressing several drivers of residual risk in this population with the multimodal mechanism of THRV-1268.'.

患有射血分数降低的心力衰竭（HFrEF）且QTc间期延长的患者面临着双重负担：在现行标准治疗下仍存在高残余发病率，心脏衰竭迅速且进行性加重，电不稳定，以及心源性猝死风险升高。这笔融资使我们能够利用THRV-1268的多模式机制，开始解决该人群残余风险的多个驱动因素。

Long QT Syndrome Program Update

长QT综合征项目更新

The Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome (NCT07277582) has completed enrollment of its first efficacy cohort, with data expected in early 2027. In the third quarter of 2026, the IDMC reviewed available Wave II safety and pharmacokinetic data and recommended continuation without modification.

THRV-1268 治疗长QT综合征的 Wave II 二期/三期研究（NCT07277582）已完成首个疗效队列的入组，预计将于2027年初公布数据。在2026年第三季度，独立数据监查委员会（IDMC）审查了现有的 Wave II 安全性和药代动力学数据，并建议无需修改继续开展研究。

No serious adverse events have been reported. The Company has submitted a protocol amendment to its U.S. FDA IND to include patients with Long QT Syndrome Type 3, further broadening a study that is now open to participants aged 15 years and older..

未报告严重不良事件。公司已向美国食品药品监督管理局（FDA）提交研究方案修正案，以纳入3型长QT综合征患者，进一步扩大目前面向15岁及以上参与者的研究范围。

Upcoming Presentations at AHA Scientific Sessions 2026

2026年美国心脏协会科学会议即将举行的报告

Thryv will present new data at the American Heart Association Scientific Sessions 2026, taking place November 6–9, 2026 at the McCormick Place Convention Center in Chicago, IL.

Thryv 将在2026年美国心脏协会科学会议上发布新数据，该会议将于2026年11月6日至9日在伊利诺伊州芝加哥的麦考密克展览中心举行。

Late-Breaking Basic Science

最新基础科学进展

SGK1 Inhibition, Monotherapy Or In Combination With Incretin Agonism, Targets Residual Risk In Cardiometabolic Heart Failure

SGK1抑制，无论是单药治疗还是与肠促胰岛素激动剂联合用药，均针对心脏代谢性心力衰竭中的残余风险

Poster Presentation

海报展示

What is the Lived Experience and Symptom Burden of Patients with Long QT Syndrome Type 2 & Type 3? Initial Findings from the myQTwave National Survey

2型与3型长QT综合征患者的生活体验及症状负担：myQTwave全国调查的初步结果

About Thryv Therapeutics Inc.

关于Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. SGK1 sits at the intersection of electrical and structural heart disease, where electrical instability drives the inflammation and fibrosis that lead to adverse structural remodeling.

Thryv Therapeutics Inc. 是一家处于临床阶段的生物技术公司，正在推进一系列强效、选择性血清和糖皮质激素调节激酶1（SGK1）抑制剂的开发，作为针对遗传性通道病、心脏代谢疾病和心肌病的精准疗法。SGK1 处于心脏电生理异常与结构性心脏病的交汇点，其中电不稳定性驱动炎症和纤维化，进而导致不良的结构重塑。

Thryv's lead candidate, THRV-1268, is being evaluated in two clinical trials: Wave II, a Phase 2/3 study in patients with Long QT Syndrome Type 2 (LQT2) and Type 3 (LQT3), and ASPIRE-HF, a Phase 2a study in heart failure with reduced ejection fraction (HFrEF). For more information, visit .

Thryv公司的主要候选药物THRV-1268正在两项临床试验中接受评估：Wave II，一项针对2型长QT综合征（LQT2）和3型长QT综合征（LQT3）患者的2/3期研究；以及ASPIRE-HF，一项针对射血分数降低的心力衰竭（HFrEF）患者的2a期研究。欲了解更多信息，请访问。

www.thryvtrx.com

www.thryvtrx.com

.

。

SOURCE Thryv Therapeutics Inc.

来源：Thryv Therapeutics Inc.